Akums Signs INR 1,760 Cr CDMO Agreement with Leading Global Pharma Company

The deal, valued at approximately Euro 200 million (INR 1,760 Cr), aims to expand Akums' presence in regulated markets.

Akums Drugs and Pharmaceuticals has signed a significant contract manufacturing and development (CDMO) agreement with a leading global pharmaceutical company to produce and supply selected oral liquid formulations to the European market. 

The deal, valued at approximately Euro 200 million (INR 1,760 Cr), aims to expand Akums' presence in regulated markets.

As part of the agreement, Akums will manufacture and supply multiple SKUs of oral liquid formulations, which the pharmaceutical company will market across various European countries. 

The commercial supply of these products is scheduled to begin in 2027 and will continue until 2032.

In addition to manufacturing, Akums will pursue European approvals for its oral liquid formulation manufacturing site. The approval process for both the site and product dossiers is expected to be completed by 2026. 

Akums currently has two sites that European regulators have approved for injectable and oral solid formulations. 

This new development strengthens Akums' capabilities in securing European certifications for more dosage forms, further solidifying its position in the global market.

Financial Details

Akums will receive an upfront payment of Euro 100 million (INR 880 Cr) for product development and securing site approvals from European authorities. 

The deal also provides significant opportunities for Akums to tap into the European pharmaceutical market and further expand its presence in other regulated territories.

Sanjeev Jain, Managing Director of Akums, said, “It gives us immense pleasure to enter into a strategic collaboration to manufacture and supply a globally renowned brand for one of the largest multinational pharma companies. This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.”

Jain further explained the broader implications of the deal, saying, “These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust. This association is the testimony of our manufacturing excellence and our world-class R&D capabilities. With this, we will add one more dosage form to our portfolio, which can be offered in the European market. Akums already have a European-approved facility for tablets, hard gelatin capsules, sachets, ampoules, vials, eye drops, and dry powder injections.”